Tivdak
Exelixis Abandons Tissue Factor-Targeting ADC Due to Competition from Tivdak
Exelixis, tissue factor-targeting ADC, Tivdak, biotech, pharmaceuticals, drug development
FDA Grants Full Approval to Pfizer’s Tivdak for Advanced Cervical Cancer Treatment
FDA, Pfizer, Tivdak, full approval, advanced cervical cancer, treatment, regulatory tracker